Angelo Delmonte

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

Luis Paz‐Ares, Mikhail Dvorkin, Yuanbin Chen et al. · The Lancet · 2019 · 2.1K citations

Platinum–etoposide Versus Platinum–etoposide, Medicine, Pharmacology +6

Brigatinib versus Crizotinib in <i>ALK</i> -Positive Non–Small-Cell Lung Cancer

D. Ross Camidge, Hye Ryun Kim, Myung‐Ju Ahn et al. · New England Journal of Medicine · 2018 · 945 citations · Full text

Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial

Jonathan W. Goldman, Mikhail Dvorkin, Yuanbin Chen et al. · The Lancet Oncology · 2020 · 662 citations · Full text

Platinum–etoposide Versus Platinum–etoposide, Medicine, Pathology +6

Brigatinib Versus Crizotinib in Advanced ALK Inhibitor–Naive ALK-Positive Non–Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial

D. Ross Camidge, Hye Ryun Kim, Myung‐Ju Ahn et al. · Journal of Clinical Oncology · 2020 · 361 citations · Full text

Brigatinib Versus Crizotinib in ALK Inhibitor–Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial

D. Ross Camidge, Hye Ryun Kim, Myung‐Ju Ahn et al. · Journal of Thoracic Oncology · 2021 · 350 citations · Full text